APOL1 and focal segmental glomerulosclerosis: Continuous treatment with interferon, a potent stimulator of APOL1 expression, has been shown to induce FSGS in individuals with high-risk APOL1 genotypes (Markowitz et al., 2010; Nichols et al., 2015).